Aimfinity Investment Corp. I (AIMTF) adds one-month Docter deal extension via $500 note

Rhea-AI Filing Summary

Aimfinity Investment Corp. I disclosed that it issued a $500 unsecured promissory note to I-Fa Chang, a manager of its sponsor’s LLC, to fund a monthly extension payment into the SPAC trust account. This payment allows Aimfinity to extend the deadline to complete its initial business combination by one month, from December 28, 2025 to January 28, 2026, representing the third of up to nine one‑month extensions authorized under a prior charter amendment.

Under an existing exchange agreement, the note’s outstanding balance will automatically convert into PubCo ordinary shares at $10.00 per share if the business combination between Aimfinity and Docter Inc. closes, unless repaid earlier. The note was issued under a private offering exemption from registration, and the company also furnished a press release announcing the new extension while reiterating extensive forward‑looking statement and transaction risk disclosures.

Insights

SPAC and capital markets analyst

Aimfinity uses a small sponsor loan to buy another month to close its Docter deal.

Aimfinity Investment Corp. I obtained a $500 unsecured promissory note from sponsor designee I-Fa Chang to fund a monthly extension payment into the SPAC trust. This extends the outside date to complete its initial business combination from December 28, 2025 to January 28, 2026, and is described as the third of up to nine one‑month extensions approved in an earlier charter amendment.

The note is tied economically to the planned merger with Docter Inc.. If that business combination closes, the outstanding balance will automatically convert into PubCo ordinary shares at a conversion price of $10.00 per share, unless repaid in whole or part before closing. The transaction was conducted under a Section 4(a)(2) private‑offering exemption, underscoring that it is a sponsor‑level funding step rather than a broad public capital raise.

The company also furnished a press release announcing the extension and repeated detailed forward‑looking statement and risk factor language around the Docter transaction, including the possibility that regulatory approvals, integration challenges, market competition, and retention of customers and employees could affect outcomes. The actual impact for investors depends on whether the additional month, and any further extensions, ultimately result in completion of the business combination on the disclosed terms.

false 0001903464 00-0000000 0001903464 2025-12-28 2025-12-28 0001903464 AIMTF:UnitsConsistingOfOneNewUnitAndOneClass1RedeemablewarrantEachExercisableForOneClassAordinaryShareAtExercisePriceOf11.50Member 2025-12-28 2025-12-28 0001903464 AIMTF:NewUnitsConsistingOfOneClassOrdinaryShareAndOnehalfOfOneClass2RedeemableWarrantEachFullExercisableForOneClassAordinaryShareAtExercisePriceOf11.50Member 2025-12-28 2025-12-28 0001903464 AIMTF:Class1RedeemableWarrantsEachExercisableForOneClassAordinaryShareAtExercisePriceOf11.50Member 2025-12-28 2025-12-28 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): December 30, 2025 (December 28, 2025)

AIMFINITY INVESTMENT CORP. I

(Exact name of registrant as specified in its charter)

Cayman Islands		001-41361		N/A
(State or other jurisdiction		(Commission File Number)		(IRS Employer
of incorporation)				Identification Number)

221 W 9th St, PMB 235
Wilmington, Delaware 19801

(Address of principal executive offices)

(425) 365-2933

(Registrant’s telephone number, including area code)

(Former name or former address, if changed since last report.)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☒ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act.

Title of each class		Trading Symbol		Name of each exchange on which registered
Units, consisting of one New Unit and one Class 1 redeemable warrant, each exercisable for one Class A ordinary share at an exercise price of $11.50		AIMUF		OTC Market Group, Inc.
New Units, consisting of one Class A ordinary share and one-half of one Class 2 redeemable warrant, each full exercisable for one Class A ordinary share at an exercise price of $11.50		AIMTF		OTC Market Group, Inc.
Class 1 redeemable warrants, each exercisable for one Class A ordinary share at an exercise price of $11.50		AIMWF		OTC Market Group, Inc.

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 2.03 Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant

On October 27, 2025, Aimfinity Investment Corp. I, a Cayman Islands exempted company (the “Company” or “AIMA”), held an extraordinary general meeting (the “EGM”), where the shareholders of the Company approved an amendment (the “Extension Amendment”) to the Company’s fourth amended and restated memorandum and articles of associations (the “Charter”) to allow the Company until October 28, 2025 to consummate an initial business combination and may elect to extend the period to consummate an initial business combination up to nine times, each by an additional one-month period (each, a “Monthly Extension”), for a total of up to nine months to July 28, 2026, by depositing into the Company’s trust account (the “Trust Account”) $500 for each one-month extension.

On December 28, 2025, the Company issued an unsecured promissory note of $500 (the “Note”) to I-Fa Chang, a member and manager of Aimfinity Investment LLC, the sponsor of the company (the “Sponsor”), as the Sponsor’s designee, to evidence the payments made for $500 (the “New Monthly Extension Payment”) to be deposited into the Trust Account for the public shareholders, which enables the Company to extend the period of time it has to consummate its initial business combination by one month from December 28, 2025 to January 28, 2026 (the “New Extension”). The New Extension is the third of the up to nine Monthly Extensions permitted under the Extension Amendment.

Pursuant to the Note, and a certain exchange agreement, dated April 8, 2025, by and among the Company, Mr. Chang and certain other parties to the Merger Agreement, upon the closing of the Business Combination (as defined below) by and between the Company and Docter Inc., a Delaware corporation, the balance of the Note, unless repaid in part or in full, will automatically be exchanged for such number of PubCo (as defined below) ordinary shares at a conversion price of $10.00 per share. The Note was issued pursuant to the exemption from registration under Section 4(a)(2) of the Securities Act of 1933, as amended (the “Securities Act”).

A copy of the Note is filed as Exhibit 10.1 to this Current Report on Form 8-K and is incorporated herein by reference. The disclosures set forth in this Item 2.03 are intended to be summaries only and are qualified in their entirety by reference to the Note.

Item 3.02 Unregistered Sales of Equity Securities.

The information disclosed under Item 2.03 of this Current Report on Form 8-K is incorporated by reference into this Item 3.02 to the extent required herein.

Item 7.01 Regulation FD Disclosure.

On December 30, 2025, the Company issued a press release (the “Press Release”) announcing the New Extension. A copy of the Press Release is furnished as Exhibit 99.1 hereto. The information in this Item 7.01 and Exhibit 99.1 furnished hereto shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act or the Exchange Act, except as expressly set forth by specific reference in such filing.

IMPORTANT NOTICES

As disclosed previously on the Current Report on Form 8-K filed with the Securities and Exchange Commission (the “SEC”) on October 16, 2023, on October 13, 2023, AIMA entered into that certain Merger Agreement, with Docter, Aimfinity Investment Merger Sub I (the “Purchaser” or “PubCo”), and Aimfinity Investment Merger Sub II, Inc. (the “Merger Sub”), pursuant to which AIMA will complete a business combination (the “Business Combination”) with Docter that involves a reincorporation merger and an acquisition merger.

1

This Current Report on Form 8-K contains certain “forward-looking statements” within the meaning of the Securities Act and the Exchange Act. Statements that are not historical facts, including statements about the proposed transactions described above, and the parties’ perspectives and expectations, are forward-looking statements. Such statements include, but are not limited to, statements regarding the proposed transactions, including the anticipated initial enterprise value and post-closing equity value, the benefits of the proposed transaction, integration plans, expected synergies and revenue opportunities, anticipated future financial and operating performance and results, including estimates for growth, the expected management and governance of the combined company, and the expected timing of the proposed transactions. The words “expect,” “believe,” “estimate,” “intend,” “plan” and similar expressions indicate forward-looking statements. These forward-looking statements are not guarantees of future performance and are subject to various risks and uncertainties, assumptions (including assumptions about general economic, market, industry and operational factors), known or unknown, which could cause the actual results to vary materially from those indicated or anticipated.

Such risks and uncertainties include, but are not limited to: (i) risks related to the expected timing and likelihood of completion of the proposed business combination, including the risk that the transaction may not close due to one or more closing conditions to the transaction not being satisfied or waived, such as regulatory approvals not being obtained, on a timely basis or otherwise, or that a governmental entity prohibited, delayed or refused to grant approval for the consummation of the transaction or required certain conditions, limitations or restrictions in connection with such approvals; (ii) risks related to the ability of AIMA and Docter to successfully integrate the businesses; (iii) the occurrence of any event, change or other circumstances that could give rise to the termination of the applicable transaction agreements; (iv) the risk that there may be a material adverse change with respect to the financial position, performance, operations or prospects of Docter or AIMA; (v) risks related to disruption of management time from ongoing business operations due to the proposed transaction; (vi) the risk that any announcements relating to the proposed transaction could have adverse effects on the market price of AIMA’s securities; (vii) the risk that the proposed transaction and its announcement could have an adverse effect on the ability of Docter to retain customers and retain and hire key personnel and maintain relationships with their suppliers and customers and on their operating results and businesses generally; (viii) risks relating to the health monitoring device industry, including but not limited to governmental regulatory and enforcement changes, market competitions, competitive product and pricing activity; and (ix) risks relating to the combined company’s ability to enhance its products and services, execute its business strategy, expand its customer base and maintain stable relationship with its business partners. A further list and description of risks and uncertainties can be found in the prospectus filed with the SEC on April 26, 2022 relating to AIMA’s initial public offering (File No. 333-263874), the annual report of AIMA on Form 10-K for the fiscal year ended on December 31, 2024, filed with the SEC on April 15, 2025 (the “Annual Report”), and in the final prospectus/proxy statement filed with the SEC on March 6, 2025 relating to the proposed transactions (File No. 333-284658) (the “Final Prospectus”), and other documents that the parties may file or furnish with the SEC, which you are encouraged to read. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those indicated or anticipated by such forward-looking statements. Accordingly, you are cautioned not to place undue reliance on these forward-looking statements. Forward-looking statements relate only to the date they were made, and AIMA, Docter and their subsidiaries or affiliates undertake no obligation to update forward-looking statements to reflect events or circumstances after the date they were made except as required by law or applicable regulation.

2

Additional Information and Where to Find It

In connection with the proposed transactions described herein, Purchaser filed the Final Prospectus with the SEC on March 6, 2025 and AIMA held an extraordinary general meeting on March 27, 2025 where the Business Combination was approved by holders of a requisite number of ordinary shares of AIMA. Shareholders will also be able to obtain a copy of the Final Prospectus without charge from AIMA. The Final Prospectus may also be obtained without charge at the SEC’s website at www.sec.gov. INVESTORS AND SECURITY HOLDERS OF AIMA ARE URGED TO READ THESE MATERIALS (INCLUDING ANY AMENDMENTS OR SUPPLEMENTS THERETO) AND ANY OTHER RELEVANT DOCUMENTS IN CONNECTION WITH THE PROPOSED TRANSACTIONS THAT AIMA WILL FILE WITH THE SEC WHEN THEY BECOME AVAILABLE BECAUSE THEY WILL CONTAIN IMPORTANT INFORMATION ABOUT AIMA, THE COMPANY AND THE PROPOSED TRANSACTIONS.

Participants in Solicitation

AIMA, Docter, and their respective directors, executive officers, other members of management, and employees, under SEC rules, may be deemed to be participants in the solicitation of proxies of AIMA’s shareholders in connection with the proposed transactions described herein. Information regarding the persons who may, under SEC rules, be deemed participants in the solicitation of AIMA’s shareholders in connection with the proposed business combination is set forth in the Final Prospectus.

No Offer or Solicitation

This Current Report on Form 8-K is not a proxy statement or solicitation of a proxy, consent or authorization with respect to any securities or in respect of the proposed transactions described herein and shall not constitute an offer to sell or a solicitation of an offer to buy the securities of AIMA or Docter, nor shall there be any sale of any such securities in any state or jurisdiction in which such offer, solicitation, or sale would be unlawful prior to registration or qualification under the securities laws of such state or jurisdiction. No offering of securities shall be made except by means of a prospectus meeting the requirements of Section 10 of the Securities Act or an exemption therefrom. 

Additional Information and Where to Find It

In connection with the proposed transactions described herein, Purchaser filed the Final Prospectus with the SEC on March 6, 2025. The proxy statement and a proxy card will be mailed to shareholders as of a record date to be established for voting at the shareholders’ meeting of AIMA shareholders relating to the proposed transactions. Shareholders will also be able to obtain a copy of the Final Prospectus without charge from AIMA. The Final Prospectus may also be obtained without charge at the SEC’s website at www.sec.gov. INVESTORS AND SECURITY HOLDERS OF AIMA ARE URGED TO READ THESE MATERIALS (INCLUDING ANY AMENDMENTS OR SUPPLEMENTS THERETO) AND ANY OTHER RELEVANT DOCUMENTS IN CONNECTION WITH THE PROPOSED TRANSACTIONS THAT AIMA WILL FILE WITH THE SEC WHEN THEY BECOME AVAILABLE BECAUSE THEY WILL CONTAIN IMPORTANT INFORMATION ABOUT AIMA, THE COMPANY AND THE PROPOSED TRANSACTIONS. 

Participants in Solicitation

AIMA, Docter, and their respective directors, executive officers, other members of management, and employees, under SEC rules, may be deemed to be participants in the solicitation of proxies of AIMA’s shareholders in connection with the proposed transactions described herein. Information regarding the persons who may, under SEC rules, be deemed participants in the solicitation of AIMA’s shareholders in connection with the proposed business combination is set forth in the Final Prospectus.

No Offer or Solicitation

This Current Report on Form 8-K is not a proxy statement or solicitation of a proxy, consent or authorization with respect to any securities or in respect of the proposed transactions described herein and shall not constitute an offer to sell or a solicitation of an offer to buy the securities of AIMA or Docter, nor shall there be any sale of any such securities in any state or jurisdiction in which such offer, solicitation, or sale would be unlawful prior to registration or qualification under the securities laws of such state or jurisdiction. No offering of securities shall be made except by means of a prospectus meeting the requirements of Section 10 of the Securities Act or an exemption therefrom. 

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits.

Exhibit No.		Description
10.1		Promissory Note, dated December 28, 2025, issued by Aimfinity Investment Corp. I to I-Fa Chang
99.1		Press Release, dated December 30, 2025
104		Cover Page Interactive Data File (embedded within the Inline XBRL document).

3

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	Aimfinity Investment Corp. I
Date: December 30, 2025	By:	/s/ I-Fa Chang
	Name:	I-Fa Chang
	Title:	Chief Executive Officer

4

FAQ

What did Aimfinity Investment Corp. I (AIMTF) announce in this Form 8-K?

Aimfinity Investment Corp. I disclosed that it issued a $500 unsecured promissory note to sponsor designee I-Fa Chang to fund a monthly extension payment into its trust account. This payment extends the deadline to complete its initial business combination by one month, from December 28, 2025 to January 28, 2026, and is the third one‑month extension permitted under a previously approved charter amendment.

How does the new promissory note for AIMTF convert into equity?

According to the disclosure, the balance of the $500 promissory note will automatically be exchanged upon closing of the business combination between Aimfinity and Docter Inc. into PubCo ordinary shares at a conversion price of $10.00 per share, unless the note is repaid in part or in full before closing.

How many monthly extensions can Aimfinity (AIMTF) use to complete its business combination?

Shareholders previously approved an amendment allowing Aimfinity to extend its business combination deadline up to nine times, each by one month, by depositing $500 into the trust account per extension. The filing states that the December 28, 2025 extension to January 28, 2026 is the third of these potential monthly extensions.

What is the relationship between Aimfinity (AIMTF) and Docter Inc. mentioned in the 8-K?

Aimfinity previously entered into a Merger Agreement with Docter Inc., Aimfinity Investment Merger Sub I (the Purchaser or PubCo), and Aimfinity Investment Merger Sub II, Inc. to complete a business combination that includes a reincorporation merger and an acquisition merger. The filing notes that an extraordinary general meeting on March 27, 2025 approved the business combination by the requisite number of Aimfinity shareholders.

How was the new Aimfinity (AIMTF) note treated under U.S. securities laws?

The filing states that the $500 promissory note issued to I-Fa Chang was offered pursuant to an exemption from registration under Section 4(a)(2) of the Securities Act of 1933, indicating it was structured as a private offering rather than a registered public offering.

Did Aimfinity (AIMTF) issue any public communication about the new extension?

Yes. On December 30, 2025, Aimfinity issued a press release announcing the new one‑month extension of the business combination deadline. The press release is furnished as Exhibit 99.1, and the company notes that this information is furnished rather than filed for purposes of Section 18 of the Exchange Act.